We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hoth Surges on Collaboration With Voltron for COVID-19 Vaccine
Read MoreHide Full Article
Shares of clinical-stage biopharmaceutical company, Hoth Therapeutics, Inc. (HOTH - Free Report) , surged 35.26% after it announced that it has reached an agreement with Voltron Therapeutics, Inc. to form a joint venture for a Self-Assembling Vaccine (SAV) for the potential prevention of the coronavirus (COVID-19).
The joint entity will be called HaloVax. Based on VaxCelerate, this SAV platform was exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). The VaxCelerate vaccine platform enables the rapid generation and pre-clinical testing of a new vaccine against specific pathogen targets.
The technology has obtained funding from the Department of Defense (DoD) and demonstrated proof of concept in Lassa Fever, which is an emerging infectious disease.
Both companies will jointly explore and develop this SAV technology as a means to help patients at risk of being infected with COVID-19. The vaccine focuses on both DNA and internal/external mutated proteins providing the immune system with more potential targets to attack.
Per the agreement, Hoth shall be granted the right to receive single-digit royalties from the sale of any products developed. It shall also have the right to acquire up to a 30% equity interest in HaloVax.
Hoth’s shares have lost 39.6% in the year so far compared with the industry’s 16.6% decline.
Given the widespread outbreak of COVID-19, many pharma/biotech companies are joining the race to develop treatments for the same. In particular, efforts to develop a vaccine to combat this deadly virus have accelerated in the last couple of weeks and Hoth is the latest company to join this bandwagon. Earlier, Moderna, Inc., (MRNA - Free Report) dosed the first participant in the phase I study of mRNA vaccine (mRNA-1273) against SARS-CoV-2. A few others like Novavax, Inc. (NVAX - Free Report) and Inovio Pharmaceuticals, Inc. (INO - Free Report) are developing vaccines to address this disease. Big pharmas like Johnson & Johnson and GlaxoSmithKline are making efforts as well to develop a vaccine.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Hoth Surges on Collaboration With Voltron for COVID-19 Vaccine
Shares of clinical-stage biopharmaceutical company, Hoth Therapeutics, Inc. (HOTH - Free Report) , surged 35.26% after it announced that it has reached an agreement with Voltron Therapeutics, Inc. to form a joint venture for a Self-Assembling Vaccine (SAV) for the potential prevention of the coronavirus (COVID-19).
The joint entity will be called HaloVax. Based on VaxCelerate, this SAV platform was exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). The VaxCelerate vaccine platform enables the rapid generation and pre-clinical testing of a new vaccine against specific pathogen targets.
The technology has obtained funding from the Department of Defense (DoD) and demonstrated proof of concept in Lassa Fever, which is an emerging infectious disease.
Both companies will jointly explore and develop this SAV technology as a means to help patients at risk of being infected with COVID-19. The vaccine focuses on both DNA and internal/external mutated proteins providing the immune system with more potential targets to attack.
Per the agreement, Hoth shall be granted the right to receive single-digit royalties from the sale of any products developed. It shall also have the right to acquire up to a 30% equity interest in HaloVax.
Hoth’s shares have lost 39.6% in the year so far compared with the industry’s 16.6% decline.
Given the widespread outbreak of COVID-19, many pharma/biotech companies are joining the race to develop treatments for the same. In particular, efforts to develop a vaccine to combat this deadly virus have accelerated in the last couple of weeks and Hoth is the latest company to join this bandwagon. Earlier, Moderna, Inc., (MRNA - Free Report) dosed the first participant in the phase I study of mRNA vaccine (mRNA-1273) against SARS-CoV-2. A few others like Novavax, Inc. (NVAX - Free Report) and Inovio Pharmaceuticals, Inc. (INO - Free Report) are developing vaccines to address this disease. Big pharmas like Johnson & Johnson and GlaxoSmithKline are making efforts as well to develop a vaccine.
Hoth currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>